Isaac Health GUIDE model has launched – click here to book

 

The best care for every brain™

Talk to specialist

Resources

Independent advisors to the FDA recommend Eli Lilly’s Alzheimer’s drug donanemab

Resources / By

June 10, 2024 – On Monday, a panel of independent advisors to the Food and Drug Administration (FDA) endorsed Eli Lilly’s new Alzheimer’s drug, donanemab. This recommendation paves the way for donanemab to receive FDA approval in the U.S. later this year, marking a significant milestone in the battle against a disease that affects millions …

Independent advisors to the FDA recommend Eli Lilly’s Alzheimer’s drug donanemab Read More »

CaringKind and Isaac Health Partner to Deliver Comprehensive Dementia Care through the GUIDE Model

Press releases, Resources / By

NEW YORK, April 17, 2024 – Isaac Health, a leading national provider of brain health and dementia care, is thrilled to expand their existing relationship with New York-headquartered CaringKind to offer individuals and families affected by dementia new support provided through the Centers for Medicare & Medicaid Services’ (CMS) Guiding an Improved Dementia Experience (GUIDE) …

CaringKind and Isaac Health Partner to Deliver Comprehensive Dementia Care through the GUIDE Model Read More »

Isaac Health is an accepted participant in CMS GUIDE Model Program

Press releases, Resources / By

NEW YORK, New York, April 9, 2024 – Isaac Health, a leading national provider of brain health and dementia care, has been accepted in the established and new model tracks of the ​​Centers for Medicare & Medicaid Services’ (CMS) Guiding an Improved Dementia Experience (GUIDE) Model.  The GUIDE Model focuses on enhancing care for individuals …

Isaac Health is an accepted participant in CMS GUIDE Model Program Read More »

Isaac Health joins ALZ-NET as a participating telehealth site

Resources / By

Isaac Health has recently become a participating site in the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET). Sponsored by the Alzheimer’s Association and managed by the American College of Radiology, ALZ-NET is a collaborative effort to improve brain health outcomes across the nation and drive innovation in the ways we care for and treat Alzheimer’s disease and other dementias.

Utilization management

White Paper on cost implications of Leqembi and other anti-amyloid drugs for payers and ACOs and options for utilization management

Dummy category, Magazine, Press releases, Resources, Uncategorized / By

Introduction: The recent full approval of Lecanemab (Leqembi) by the FDA has ushered in a new era in the treatment of Alzheimer’s disease. As the first disease-modifying treatment to receive such approval, Leqembi offers hope to patients with early-stage Alzheimer’s. However, its adoption poses cost implications for payers and risk-bearing health systems. In a newly …

White Paper on cost implications of Leqembi and other anti-amyloid drugs for payers and ACOs and options for utilization management Read More »

Neurologist with brain scan

Leqembi – Implications for Health Insurance Payers: A Comprehensive Analysis

Leave a Comment / Magazine, Press releases, Resources / By

Introduction: On July 6, 2023, the FDA granted full approval to Lecanemab (Leqembi), marking a significant milestone as the first disease-modifying treatment for Alzheimer’s disease to receive such approval. This white paper aims to inform health insurance employees about the implications of Leqembi’s approval and offer insights into coverage considerations and potential cost implications. Coverage …

Leqembi – Implications for Health Insurance Payers: A Comprehensive Analysis Read More »

Image of FDA Building

FAQ About Leqembi

Leave a Comment / Press releases, Resources / By

About Leqembi Leqembi is the first of (very likely) many forthcoming drugs that will be revolutionizing the landscape of early stage Alzheimer’s disease. With its traditional (full) FDA approval come new questions from our patients and community surrounding its availability, manufacturer, purchasing options, working mechanism, insurance coverage, and comparisons with other medications. Our doctors here …

FAQ About Leqembi Read More »

President Carter and First Lady Rosalynn Carter dance at the annual Congressional Christmas Ball at the White House in 1978 in Washington, D.C. (Ira Schwarz / Associated Press)

Insights on former First Lady, Rosalynn Carter’s Diagnosis

Leave a Comment / Magazine, Press releases, Resources / By

Rosalynn Carter, the former First Lady and a prominent advocate for mental health care, has been diagnosed with dementia, as announced by the Carter Center and reported by the New York Times. This revelation follows her husband, former President Jimmy Carter’s decision to enter hospice care. Despite the diagnosis, Mrs. Carter, at 95 years old, …

Insights on former First Lady, Rosalynn Carter’s Diagnosis Read More »

Select evidence for the prevention of Alzheimer’s Disease

Resources / By

FINGER study on Alzheimer prevention suggesting a multidomain intervention is effective in preventing a significant proportion of Alzheimer cases: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60461-5/fulltext Global study based on the FINGER study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222931/ CAIDE study on addressable Alzheimer Risk Factors: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(06)70537-3/fulltext Helpful overview of all risk factors and prevention recommendations: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2244657/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514088/ The approach of the Weill Cornel Alzheimer prevention …

Select evidence for the prevention of Alzheimer’s Disease Read More »

COMPANY

SERVICES

LEGAL

CONTACT US

Facebook-f Linkedin
Designed with love Virtu Digital

Copyright 2024 © All rights Reserved 2GHealth Inc.

442 5th Avenue #1520, New York, NY 10018-2794

If you're having a medical or mental health emergency, call 911 or go to your local emergency room.

Join our community

* indicates required

Request patient flyers